Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | GRM5 | P41594 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | TMEM97 | Q5BJF2 | 5/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4312452 | 0.89 | GRM5 (0.51) | MEN1KMT2ANPSR1GRM5SMN1; SMN2 | |
| SCHEMBL6688964 | 0.86 | GRM5 (0.57) | MEN1KMT2ANPSR1GRM5SMN1; SMN2 | |
| SCHEMBL11957019 | 0.81 | GRM5 (0.57) | MEN1KMT2ANPSR1GRM5SMN1; SMN2 | |
| SCHEMBL19046612 | 0.79 | GRM5 (0.58) | MEN1KMT2ANPSR1GRM5SMN1; SMN2 | |
| SCHEMBL20014800 | 0.79 | GRM5 (0.50) | MEN1KMT2ANPSR1GRM5SMN1; SMN2 | |
| SCHEMBL12240997 | 0.79 | GRM5 (0.55) | MEN1KMT2ANPSR1GRM5SMN1; SMN2 | |
| SCHEMBL17886619 | 0.79 | GRM5 (0.55) | MEN1KMT2ANPSR1GRM5SMN1; SMN2 | |
| SCHEMBL9381267 | 0.79 | GRM5 (0.55) | MEN1KMT2ANPSR1GRM5SMN1; SMN2 | |
| SCHEMBL21078113 | 0.78 | GRM5 (0.57) | MEN1KMT2ANPSR1GRM5SMN1; SMN2 | |
| SCHEMBL8315932 | 0.78 | MEN1 (0.57) | MEN1KMT2ANPSR1GRM5SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3255993-B1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME (US) | 2021-01-27 | — | — | EP | disclosed |
| US-10160751-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. | 2018-12-25 | — | — | US | disclosed |
| US-20180016263-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME LLC | 2018-01-18 | — | — | US | disclosed |
| EP-3255993-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | Merck Sharp & Dohme Corp. (US) | 2017-12-20 | — | — | EP | disclosed |
| US-9714231-B2 | Pyrrolidine GPR40 modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-07-25 | — | — | US | disclosed |
| US-9604964-B2 | Dihydropyrazole GPR40 modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-03-28 | — | — | US | disclosed |
| EP-2925741-B1 | PYRROLIDINE GPR40 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2016-10-26 | — | — | EP | disclosed |
| EP-2925749-B1 | DIHYDROPYRAZOLE GPR40 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2016-10-26 | — | — | EP | disclosed |
| US-20160297797-A1 | DIHYDROPYRAZOLE GPR40 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2016-10-13 | — | — | US | disclosed |
| US-20160280680-A1 | PYRROLIDINE GPR40 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2016-09-29 | — | — | US | disclosed |
| US-8183245-B2 | Pyrazine substituted pyrrolopyridines as inhibitors of JAK and PDK1 | MERCK SHARP & DOHME CORP. (US) | 2012-05-22 | — | — | US | disclosed |
| US-20110230458-A1 | PHENYL-HETEROARYL DERIVATIVES AND METHODS OF USE THEREOF | TRANSTECH PHARMA, INC. (US) | 2011-09-22 | — | — | US | disclosed |
| WO-2011103091-A1 | PHENYL-HETEROARYL DERIVATIVES AND METHODS OF USE THEREOF | TRANSTECH PHARMA, INC. (US) | 2011-08-25 | — | — | WO | disclosed |
| US-20110184013-A1 | Imidazo[1,2-a]Pyridine Compounds As Receptor Tyrosine Kinase Inhibitors | ARRAY BIOPHARMA, INC. | 2011-07-28 | — | — | US | disclosed |
| WO-2011084402-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-07-14 | — | — | WO | disclosed |
| EP-2334677-A1 | TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2011-06-22 | — | — | EP | disclosed |
| US-20110144085-A1 | TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-06-16 | — | — | US | disclosed |
| US-20100210623-A1 | THERAPEUTIC COMPOUNDS | MERCK SHARP & DOHME CORP. | 2010-08-19 | — | — | US | disclosed |
| WO-2010039825-A2 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2010-04-08 | — | — | WO | disclosed |
| WO-2010022076-A1 | TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2010-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210623-A1 | THERAPEUTIC COMPOUNDS | JAK2, PDK1, JAK3 | MEN1 2558/4885KMT2A 941/4885NPSR1 4198/4885 |
| US-10160751-B2 | Inhibitors of the renal outer medullary potassium channel | KCNJ11, KCNJ1, SLC9A1 | MEN1 354/4885KMT2A 1703/4885NPSR1 683/4885 |
| US-20110230458-A1 | PHENYL-HETEROARYL DERIVATIVES AND METHODS OF USE THEREOF | AGER, PSEN2, PSEN1 | MEN1 2797/4885KMT2A 4080/4885NPSR1 641/4885 |
| US-20160297797-A1 | DIHYDROPYRAZOLE GPR40 MODULATORS | GPR55, GPR65, GPR35 | MEN1 3698/4885KMT2A 3776/4885NPSR1 142/4885 |
| US-20180016263-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | KCNJ11, KCNJ1, SLC9A1 | MEN1 354/4885KMT2A 1703/4885NPSR1 683/4885 |
| US-20110144085-A1 | TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS | PIM1, PIM2, PIM3 | MEN1 3598/4885KMT2A 1090/4885NPSR1 806/4885 |
| US-20160280680-A1 | PYRROLIDINE GPR40 MODULATORS | GPR55, GPR65, GPR27 | MEN1 4012/4885KMT2A 3563/4885NPSR1 46/4885 |
| US-20110184013-A1 | Imidazo[1,2-a]Pyridine Compounds As Receptor Tyrosine Kinase Inhibitors | PIM1, PIM2, PIM3 | MEN1 3776/4885KMT2A 1166/4885NPSR1 1421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.